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Background: Gastrointestinal graft–versus-host disease (GvHD) is a potentially life-threatening complication after
allogeneic stem cell transplantation (SCT). Since therapeutic options are still limited, a prophylactic approach seems
to be warranted.
Methods: In this randomised, double-blind-phase III trial, we evaluated the efficacy of budesonide in the prophylaxis
of acute intestinal GvHD after SCT. The trial was registered at https://clinicaltrials.gov, number NCT00180089.
Patients were randomly assigned to receive either 3 mg capsule three times daily oral budesonide or placebo.
Budesonide was applied as a capsule with pH-modified release in the terminal ileum. Study medication was
administered through day 56, follow-up continued until 12 months after transplantation. If any clinical signs of
acute intestinal GvHD appeared, an ileocolonoscopy with biopsy specimens was performed.
Results: The crude incidence of histological or clinical stage 3–4 acute intestinal GvHD until day 100 observed
in 91 (n =48 budesonide, n =43 placebo) evaluable patients was 12.5% (95% CI 3-22%) under treatment with
budesonide and 14% (95% CI 4-25%) under placebo (p = 0.888). Histologic and clinical stage 3–4 intestinal GvHD
after 12 months occurred in 17% (95% CI 6-28%) of patients in the budesonide group and 19% (CI 7-32%) in the
placebo group (p = 0.853). Although budesonide was tolerated well, we observed a trend towards a higher rate
of infectious complications in the study group (47.9% versus 30.2%, p = 0.085). The cumulative incidences at
12 months of intestinal GvHD stage >2 with death as a competing event (budesonide 20.8% vs. placebo 32.6%,
p = 0.250) and the cumulative incidence of relapse (budesonide 20.8% vs. placebo 16.3%, p = 0.547) and non-relapse
mortality (budesonide 28% (95% CI 15-41%) vs. placebo 30% (95% CI 15-44%), showed no significant difference within
the two groups (p = 0.911). The trial closed after 94 patients were enrolled because of slow accrual. Within the
limits of the final sample size, we were unable to show any benefit for the addition of budesonide to standard
GvHD prophylaxis.
Conclusions: Budesonide did not decrease the occurrence of intestinal GvHD in this trial. These results imply most
likely that prophylactic administration of budenoside with pH-modified release in the terminal ileum is not effective.
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Acute intestinal GvHD is a frequent complication after
allogeneic stem cell transplantation (SCT) and remains a
major cause of morbidity and mortality. In spite of
standard GvHD prophylaxis between 20 to 80% of the
patients suffer from clinically relevant acute GvHD
[1-9]. Whereas acute GvHD with affection of the skin
and/or liver rarely becomes life-threatening, acute intes-
tinal GvHD represents one of the most frequent causes of
death after allogeneic SCT. Severe cases may suffer from
watery stools up to a volume of several litres, bloody stools
or ileus. The median survival of correspondent patients
with acute GvHD grade 3 and 4 constitute between
two and three months only [8]. Therefore a prophylactic
approach seems to be warranted.
Budesonide has demonstrated its efficacy in the treat-
ment of various chronic inflammatory bowel diseases
[10-20]. It is a locally acting steroid derived from 16α-
hydroxyprednisolon with strong anti-inflammatory, anti-
exudative and anti-oedematous characteristics. The local
effect of budesonide is comparable to prednisolone
[11,15,21]. It underlies a high first pass effect in the
liver and therefore is associated with fewer side effects
compared to corticosteroids with systemic efficacy.
The bioavailability accounts for 9 to 12%. Some reports
of the effectiveness of budesonide and other locally
acting steroids in acute GvHD already exist [22,23]. A
study on the potential value of budesonide for the prophy-
laxis of intestinal GvHD has not been performed.
Methods
Study design and patients
The PROGAST trial, a study of budesonide as an agent
for prevention of acute intestinal GvHD was a rando-
mised, double-blind, placebo-controlled multicentre trial.
The study was conducted at 3 centres from March 2003
through May 2007. The medical ethics committee of the
TU Dresden and the ethics committee at Charité, Berlin
approved the protocol, and all patients provided written
informed consent. The trial was registered at https://
clinicaltrials.gov, number NCT00180089.
Eligible male and female patients were at least 12 years
of age and in preparation for related or unrelated
allogeneic SCT. The stem cell donors –related or
unrelated- were selected based on the compatibility
for 10 HLA alleles (HLA-A, −B, −C, DRB1 and DQB1)
by high-resolution (2 digit for class I, 4 digit for class
II) DNA typing. One single allele mismatch was
allowed within the same broad serotype or within a
cross-reactive group. GvHD prophylaxis regimes followed
international standards with cyclosporine A or ta-
crolimus in combination with methotrexate, option-
ally combined with anti-thymocyte globulin (ATG) or
alemtuzumab.Patients who received a T-cell-depleted graft, or who
had received budesonide within 4 weeks prior to trans-
plantation, as well as patients with local gut infections,
apparent infectious disease, portal hypertension, pro-
found liver function impairment, liver cirrhosis or severe
psychiatric diseases were excluded.
Study treatment and randomisation
Patients were randomly assigned to receive either oral
budesonide (Budenofalk® 3 mg, Dr. Falk Pharma GmbH,
Freiburg, Germany) at a daily dose of 9 mg (3 mg TID)
or placebo. Budesonide was administered as a capsule.
The galenical formulation assured a drug release accord-
ing to a pH >6.4 which resembles the pH in the terminal
ileum. Medication started one day before allogeneic SCT
and was continued until day 56. Afterwards the patients
went into a follow-up period until 12 months.
Randomisation was performed centrally with the use
of a randomisation procedure stratified according to the
relationship of the donor (related or unrelated), condi-
tioning regimens ( dosage reduced or intensive), and in-
vivo T-cell-depletion (with or without anti-thymocyte
globulin (ATG)/alemtuzumab).
Evaluation of efficacy and safety
GvHD evaluation was performed weekly starting from day
5 until day 56 after SCT and followed by visits in week 12,
16, 20, 24 and 56. Clinical signs of intestinal GvHD were
classified according to Glucksberg-classification [24] of
acute GvHD: occurrence of diarrhoea, bloody stools,
abdominal pain, nausea and vomiting. If one of these
symptoms emerged, a colonoscopy with specimens ac-
cording to a standardized protocol was performed [25].
GvHD was histologically classified following Lerner’s
classification [26]. Monitoring for adverse events using
common toxicity criteria (CTC) was performed until
12 months after transplantation.
Primary and secondary end points
The primary efficacy end point was the rate of patients
with acute intestinal GvHD > stage 2 until day 100 after
transplantation. Patients with histologic GvHD > grade 2
and patients with clinical signs of GvHD > stage 2 together
with a positive histologic result for GvHD were classified
as failures with respect to the primary end point. Sec-
ondary end points included the rate of patients with
acute intestinal GvHD > stage 2 during follow-up until
12 months after transplantation, tolerability and safety
of budesonide, severity of acute intestinal GvHD, inci-
dence of chronic intestinal GvHD and infectious compli-
cations. Survival end points were overall and relapse-free
survival, as well as relapse incidence and non-relapse
mortality.
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The study was jointly designed by haematologists and
gastroenterologists of the University Hospital Dresden.
A total of three centres participated in this trial (University
Hospital Dresden, Charité-Campus Benjamin Franklin
in Berlin, German Hospital for Diagnostics, Wiesbaden).
Data was collected and analysed by the local Coordination
Centre for Clinical Trials (KKS) in Dresden. The academic
authors vouch for the veracity and completeness of the
data and the data analyses.
Statistical analysis
For the primary end point, the rate of patients with
acute intestinal GvHD > stage 2 after transplantation a
rate of 30% for the placebo group was assumed. The
expected incidence of GI GvHD seems to depend
mainly on the frequency of endoscopic investigations.
In fact Martin and coworkers [27] could show that the
incidence of early stages of gut GvHD can be as high as
60%, especially in recipients of grafts from unrelated
donors. It was calculated that 242 patients would be
needed to provide a power of 80% in order to detect a
difference in GvHD occurrence of 15% among the two
groups (budesonide versus placebo). The software was
nQuery Advisor® 7.0.
The overall incidence of acute and chronic GvHD and
infectious complications were compared with the use ofTable 1 Demographic and clinical characteristics at baseline
Characteristic Budeso
(N = 48
Male sex - no. (%) 30 (62.5
0.662 Median age (yrs) - Mean (SD) 53.1 + 1
Duration of disease (mths) -Mean (SD) 23.4 + 3
Complete remission pre-SZT - no. (%) 18 (38.3
Basic disease - no. (%)
Myelodysplastic syndrome - MDS 5 (10.6)
Acute myeloid leucemia - AML 19 (40.4
Acute lymphoblastic leucemia - ALL 7 (14.6)
Chronic myeloid leucemia - CML 1 (2.1)
Chronic lymphocytic leucemia - CLL 1 (2.1)
Non Hodgkin lymphoma - NHL /M. Hodgkin 6 (12.8)
Multiple myeloma 3 (6.4)
Others 5 (10.6)
Chemotherapeutic conditioning - no. (%) 44 (91.7
Total body irradiation -TBI - no. (%) 27 (56.3
Dosage reduced induction regimen (%) 27 (56.3
In-vivo T-cell depletion (%) 29 (60.4
Sibling transplant (%) 17 (35.4
CMV-status positive - no. (%) 31 (64.6
0.31P value based on a chi-square test or * t-test.the chi-square test and accordingly Fisher’s exact test.
Efficacy analyses were performed according to the
intention-to-treat principle. All patients receiving at
least one dose of the study drug were included in the
safety analysis. Tolerability of budesonide was assessed
by means of CTC score. The comparison of overall and
relapse-free survival was made with Kaplan-Meier survival
analysis [28] and adjacent log-rank test between the
budesonide and the placebo group. The cumulative inci-
dence of stage 3 to 4 GI GvHD until 12 months after
transplantation was calculated with death without intes-
tinal GVHD as a competing risk [29]. Relapse incidence
and non-relapse mortality were considered as compet-
ing events. Cumulative incidences were compared with




Due to a lack of sufficient patient recruitment, the
protocol committee decided to terminate the study pre-
maturely. Of the 94 patients who underwent randomisa-
tion, 48 received budesonide and 46 received placebo.
Three patients assigned to the placebo group did not
take any study medication (2 patients withdrew their
consent; 1 patient died), thus the ITT population con-





) 29 (67.4) 0.662
2.2 52.0 + 12.9 0.660*
3.4 15.4 + 15.4 0.139*









) 36 (83.7) 0.246
) 22 (51.2) 0.627
) 24 (55.8) 0.967
) 26 (60.5) 0.994
) 15 (34.9) 0.958
) 32 (74.4) 0.31
   3 discontinued the study 
- 2 withdrew consent 
- 1 died
94 underwent randomization
46  were assigned to 
receive placebo 
   48  were assigned to 
receive budesonide  
43 were eligible for 
intention-to-treat 
analysis in the 
placebo group 
48  were eligible for 
 intention-to-treat 
 analysis in the 
 budesonide group 
Figure 1 Patient enrollment.
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multiple myeloma which was more frequent in the pla-
cebo group. A total of 91 patients completed the trial
(Figure 1).
Primary end point
Within the first 100 days after transplantation, a total of
6 patients (12.5%, 95% CI 3-22%) in the budesonide
group and 6 patients (14%, 95% CI 4-25%) in the placebo
group had experienced histologic or clinical acute intestinal
GvHD> stage 2 according to Lerner’s- and Glucksberg
classification [24,26] of intestinal GvHD. There was no
significant difference within the two groups (p = 0.888,
Table 2). With the final sample size of 91 patients the postTable 2 Incidence of acute intestinal GvHD > grade 2 until da
Acute intestinal GvHD grade 0-2 Number
%
Acute intestinal GvHD grade 3-4 Number
%
Totalhoc power to detect a 15% difference in a chi-square test
was 31% (15% acute GvHD in the treatment arm com-
pared to 30% acute GvHD in the placebo arm). The final
sample size should only permit to reveal a difference of
25% (5% acute GvHD in the experimental arm and 30%
acute GvHD in the placebo arm) with a type I error of 5%
and a power of 80%.
Nevertheless if the trial would have continued to enroll
and results continued on current trajectory there would
be no significant difference (1.5%) within the two groups.
Secondary end points
The crude incidences of histologic and clinical stage 3–








Figure 2 Cumulative incidence of gastrointestinal GvHD > stage 2 after prophylaxis with budesonid and placebo (p = 0.84).
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were 17% (n =9, 95% CI 6-28%) in the budesonide group
and 19% (n =8, 95% CI 7-32%) in the placebo group
(p = 0.853). The cumulative incidences at 12 months of
intestinal GvHD stage >2 with death as a competing event
(budesonide 20.8% vs. placebo 32.6%, p = 0.250) and the cu-
mulative incidence of relapse (budesonide 20.8% vs. placebo
16.3%, p = 0.547) and non-relapse mortality ( budesonide
28% (95% CI 15-41%) vs. placebo 30% (95% CI 15-44%),
showed no significant difference within the two groups
( p = 0.911, Figures 2 and 3).
Through month 12, the incidences of adverse events
(AE) and severe adverse events (SAE) were similar
among the two groups (Table 3). Every patient in the
budesonide group (100%) and 97.7% in the placebo
group had at least one adverse event. Classified by theFigure 3 Cumulative incidence of death after prophylaxis with budesCTC score, budesonide was tolerated. There was a sta-
tistically insignificant trend to a higher rate of overall
infectious complications until month 12 in the budeso-
nide group (47.9%) compared to placebo (30.2%), but
there was no difference in the rate of gastrointestinal in-
fections (placebo 4.6% vs. budesonide 4.4%). Further on
a statistically insignificant trend to a higher overall sur-
vival (72.9% budesonide, 62.8% placebo) in the budeso-
nide group was observed.
The incidence of chronic intestinal GvHD showed a higher
percentage in the placebo group (budesonide 6.3% (n = 3),
placebo 11.6% (n = 5), but failed to reach significance.
The distribution of the severity stages of acute intes-
tinal GvHD, as well as incidence and severity stages of
skin, liver and grades of overall GvHD showed no differ-
ence between the two groups.onid and placebo (p = 0.25).






Patients with any adverse event - no. (%) 48 (100.0) 42 (97.7) nsa
Any serious adverse event - no. (%) 13 (27.1) 13 (30.2) nsa
Infectious complications - no. (%)
Adverse event 23 (47.9) 13 (30.2) 0.085 (ns)a
Pneumonia 2 (4.2) 4 (9.3)
Sepsis 3 (6.3) 0 (0)
Serious adverse event 5 (10.4) 1 (2.3) 0.207 (ns)b
Pneumonia 2 (4.2) 1 (2.3)
Sepsis 2 (4.2) 0 (0)
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GI GvHD remains a huge problem, with few therapeutic
options. Acute GvHD is mediated by immunocompetent
donor T cells, which migrate to lymphoid tissues soon
after allogeneic stem cell transplantation. In the light of
the high mortality of severe GI GvHD which often does
not respond to steroid therapy, alternative treatments
are being actively investigated. Besides the options
of in-vivo or in-vitro T-cell-depletion, a prophylactic
pharmacologic approach seems to be the most promising.
Ideally, prophylactic treatment should not affect trans-
plantation associated mortality and the incidence of
relapse. T-cell-depleted grafts effectively reduce the
risk of acute GvHD but are associated with a higher re-
lapse rate because of the missing Graft-versus-leukemia
effect. An intensified pharmacologic prophylaxis has been
associated with an increase in the relapse rate, a higher
rate of systemic infections and a late recurrence of GvHD.
A prophylactic approach with budesonide asa locally
acting immunosuppressive treatment seems to be attractive
because of a lower risk of systemic complications during
therapy, as seen in patients with chronic inflammatory
bowel disease. Underlying rationale is a strong anti-
inflammatory local effect of budesonide on the one
hand and a high first pass effect in the liver of more
than 90%, which leads to negligible systemic effects on
the other hand.
Even though the present study suggests that oral bude-
sonide is not effective for the prevention of acute intes-
tinal GvHD, early intervention in patients with a high-risk
of gastrointestinal GvHD still seems to be an attractive
strategy.
Furthermore it should be taken into account that
the applied galenic formulation of budesonide has its
maximum effect in the terminal ileum and right-sided
colon. This is based on the pH-modified release of oral
budesonide and therefore it is not adequate for prophylaxis
of intestinal GvHD in the jejunum or proximal ileum.
Some open-label studies showed efficacy in distal ulcerativecolitis, but this finding has to be confirmed in controlled
trials [30]. Therefore it remains unclear, if budesonide has a
sufficient effect in the prophylaxis of GvHD in the distal
colon.
Besides pharmacokinetic analyses suggest that a single
dose of 9 mg budesonide may lead to a higher local con-
centration of budesonide compared to 3 mg three times
per day [31] as performed in this study and therefore,
could increase the therapeutic potential.
Overall infectious complications showed a trend to a
higher frequency in the budesonide group, but gastro-
intestinal infections were equal in both groups and reflect
better potentially side effects of locally acting budesonide.
As an additional second endpoint there was also no
difference in the incidence of liver involvement, a site
where the first-pass effect would lead to the assumption
of a local efficacy of the study compound.Conclusion
In summary, this study failed to show a significant effect
of prophylactic treatment with oral budesonide in pre-
venting gastrointestinal GvHD. This study was closed
prematurely because of slow accrual. Within the limita-
tions of the sample size, no significance difference in
outcomes were able to be detected in primary and sec-
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